Evidence map›Paper›PMID 40235861›Full record

ArticleCase reports in oncology

Clinical Response to Enfortumab Vedotin and Pembrolizumab in a Patient with Vaginal Squamous Cell Carcinoma: A Case Report.

Michael Glover, Isabel Beshar, Austin McHenry, Cornelia Ding, Oliver Dorigo, Emily Chan, Sumit A Shah

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Evaluation of HER2 and Nectin-4 Expression in Primary Vaginal Cancers.International journal of molecular sciences · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Michael GloverDivision of Medical Oncology, Department of Medicine, Stanford University, Stanford, CA, USA.
Isabel BesharDepartment of Obstetrics and Gynecology, Stanford University, Stanford, CA, USA.
Austin McHenryDepartment of Pathology, Stanford University, Stanford, CA, USA.
Cornelia DingDepartment of Clinical Pathology, University of California San Francisco, San Francisco, CA, USA.
Oliver DorigoDivision of Gynecology Oncology, Department of Obstetrics and Gynecology, Stanford Cancer Institute, Stanford University, Stanford, CA, USA.
Emily ChanDepartment of Pathology, Stanford University, Stanford, CA, USA.
Sumit A ShahDivision of Medical Oncology, Department of Medicine, Stanford University, Stanford, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Vaginal cancer is a rare yet aggressive cancer, with unmet need for novel therapeutics. Case Presentation: In this case report, we present a patient with advanced stage, HPV-positive vaginal cancer who demonstrated clinical, radiological, and molecular response to combination treatment of antibody-drug conjugate enfortumab vedotin (EV) with pembrolizumab. Conclusion: This is the first reported response to this combination therapy in vaginal cancer in the literature. The patient had positive Nectin-4 staining on evaluation, raising the possibility for future clinical application of EV in vaginal squamous cell cancer.

Indexed as

Enfortumab vedotinNectin-4PembrolizumabVaginal cancer

Identifiers

PMID40235861
PMCPMC11999660

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.